We conclude that high levels of circulating MACC1 or S100A4 transcripts at primary diagnosis (but not among follow‐up samples during surgery and adjuvant chemotherapy) are unfavorable prognostic factors for ovarian cancer patients and indicate poor prognosis. This evidence concerns the gene MACC1 and ovarian cancer.